|
1
|
Schwartzbaum JA, Fisher JL, Aldape KD and
Wrensch M: Epidemiology and molecular pathology of glioma. Nat Clin
Pract Neurol. 2:494–503. 15162006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Brada M, van den Bent MJ, Tonn JC
and Pentheroudakis G; ESMO Guidelines Working Group, : High-grade
glioma: ESMO clinical practice guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 25 (Suppl 3):iii93–iii101. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ostrom QT, Cioffi G, Gittleman H, Patil N,
Waite K, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical
report: Primary brain and other central nervous system tumors
diagnosed in the United States in 2012–2016. Neuro Oncol. 21 (Suppl
5):v1–v100. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wesseling P and Capper D: WHO 2016
classification of gliomas. Neuropathol Appl Neurobiol. 44:139–150.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Śledzińska P, Bebyn MG, Furtak J,
Kowalewski J and Lewandowska MA: Prognostic and predictive
biomarkers in gliomas. Int J Mol Sci. 22:103732021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weller M and Reifenberger G: Beyond the
World Health Organization classification of central nervous system
tumors 2016: What are the new developments for gliomas from a
clinician' perspective? Curr Opin Neurol. 33:701–706. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kristensen BW, Priesterbach-Ackley LP,
Petersen JK and Wesseling P: Molecular pathology of tumors of the
central nervous system. Ann Oncol. 30:1265–1278. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reinhardt A, Stichel D, Schrimpf D, Sahm
F, Korshunov A, Reuss DE, Koelsche C, Huang K, Wefers AK, Hovestadt
V, et al: Anaplastic astrocytoma with piloid features, a novel
molecular class of IDH wildtype glioma with recurrent MAPK pathway,
CDKN2A/B and ATRX alterations. Acta Neuropathol. 136:273–291. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ostrom QT, Kinnersley B, Wrensch MR,
Eckel-Passow JE, Armstrong G, Rice T, Chen Y, Wiencke JK, McCoy LS,
Hansen HM, et al: Sex-specific glioma genome-wide association study
identifies new risk locus at 3p21.31 in females, and finds
sex-differences in risk at 8q24.21. Sci Rep. 8:73522018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ostrom QT, Cote DJ, Ascha M, Kruchko C and
Barnholtz-Sloan JS: Adult glioma incidence and survival by race or
ethnicity in the united states from 2000 to 2014. JAMA Oncol.
4:1254–1262. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zacher A, Kaulich K, Stepanow S, Wolter M,
Köhrer K, Felsberg J, Malzkorn B and Reifenberger G: Molecular
diagnostics of gliomas using next generation sequencing of a
glioma-tailored gene panel. Brain Pathol. 27:146–159. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim HS, Kwon MJ, Song JH, Kim ES, Kim HY
and Min KW: Clinical implications of TERT promoter mutation on IDH
mutation and MGMT promoter methylation in diffuse gliomas. Pathol
Res Pract. 214:881–888. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Razis E, Kotoula V, Koliou GA,
Papadopoulou K, Vrettou E, Giannoulatou E, Tikas I, Labropoulos SV,
Rigakos G, Papaemmanoyil S, et al: Is there an independent role of
TERT and NF1 in high grade gliomas? Transl Oncol. 13:346–354. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li H: Aligning sequence reads, clone
sequences and assembly contigs with BWA-MEM. arXiv.
3:130339972013.
|
|
16
|
Li H, Handsaker B, Wysoker A, Fennell T,
Ruan J, Homer N, Marth G, Abecasis G and Durbin R; 1000 Genome
Project Data Processing Subgroup, : The sequence alignment/map
format and SAMtools. Bioinformatics. 25:2078–2079. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li MM, Datto M, Duncavage EJ, Kulkarni S,
Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ,
Younes A and Nikiforova MN: Standards and guidelines for the
interpretation and reporting of sequence variants in cancer: A
joint consensus recommendation of the association for molecular
pathology, American society of clinical oncology, and college of
American pathologists. J Mol Diagn. 19:4–23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McLaren W, Gil L, Hunt SE, Riat HS,
Ritchie GR, Thormann A, Flicek P and Cunningham F: The ensembl
variant effect predictor. Genome Biol. 17:1222016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Landrum MJ, Lee JM, Benson M, Brown GR,
Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W, et al:
ClinVar: Improving access to variant interpretations and supporting
evidence. Nucleic Acids Res. 46(D1): D1062–D1067. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tate JG, Bamford S, Jubb HC, Sondka Z,
Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E,
et al: COSMIC: The catalogue of somatic mutations in cancer.
Nucleic Acids Res. 47(D1): D941–D947. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seshan VE and Olshen AB: DNAcopy: A
package for analyzing DNA copy data. Bioconductor Vignette. 1–7.
2014.
|
|
22
|
Chen X, Schulz-Trieglaff O, Shaw R, Barnes
B, Schlesinger F, Källberg M, Cox AJ, Kruglyak S and Saunders CT:
Manta: Rapid detection of structural variants and indels for
germline and cancer sequencing applications. Bioinformatics.
32:1220–1222. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cameron DL, Schröder J, Penington JS, Do
H, Molania R, Dobrovic A, Speed TP and Papenfuss AT: GRIDSS:
Sensitive and specific genomic rearrangement detection using
positional de Bruijn graph assembly. Genome Res. 27:2050–2060.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Layer RM, Chiang C, Quinlan AR and Hall
IM: LUMPY: A probabilistic framework for structural variant
discovery. Genome Biol. 15:R842014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Grech N, Dalli T, Mizzi S, Meilak L,
Calleja N and Zrinzo A: Rising incidence of glioblastoma multiforme
in a well-defined population. Cureus. 12:e81952020.PubMed/NCBI
|
|
26
|
Nie Q, Hsiao MC, Chandok H, Rowe S, Prego
M, Meyers B, Omerza G, Hesse A, Uvalic J, Soucy M, et al: Molecular
profiling of CNS tumors for the treatment and management of
disease. J Clin Neurosci. 71:311–315. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ballester LY, Fuller GN, Powell SZ, Sulman
EP, Patel KP, Luthra R and Routbort MJ: Retrospective analysis of
molecular and immunohistochemical characterization of 381 primary
brain tumors. J Neuropathol Exp Neurol. 76:179–188. 2017.PubMed/NCBI
|
|
28
|
Zeng C, Wang J, Li M, Wang H, Lou F, Cao S
and Lu C: Comprehensive molecular characterization of Chinese
patients with glioma by extensive next-generation sequencing panel
analysis. Cancer Manag Res. 13:3573–3588. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zheng S, Alfaro-Munoz K, Wei W, Wang X,
Wang F, Eterovic AK, Shaw KRM, Meric-Bernstam F, Fuller GN, Chen K,
et al: Prospective clinical sequencing of adult glioma. Mol Cancer
Ther. 18:991–1000. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gillet E, Alentorn A, Doukouré B,
Mundwiller E, van Thuijl HF, Reijneveld JC, Medina JA, Liou A,
Marie Y, Mokhtari K, et al: TP53 and p53 statuses and their
clinical impact in diffuse low grade gliomas. J Neurooncol.
118:131–139. 2014.PubMed/NCBI
|
|
31
|
Pessôa IA, Amorim CK, Ferreira WAS, Sagica
F, Brito JR, Othman M, Meyer B, Liehr T and de Oliveira EHC:
Detection and correlation of single and concomitant TP53, PTEN, and
CDKN2A alterations in gliomas. Int J Mol Sci. 20:26582019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Parsons DW, Jones S, Zhang X, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et
al: An integrated genomic analysis of human glioblastoma
multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Park C, Kim TM, Bae JM, Yun H, Kim JW,
Choi SH, Lee ST, Lee JH, Park SH and Park CK: Clinical and genomic
characteristics of adult diffuse midline glioma. Cancer Res Treat.
53:389–398. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Reis GF, Pekmezci M, Hansen HM, Rice T,
Marshall RE, Molinaro AM, Phillips JJ, Vogel H, Wiencke JK, Wrensch
MR, et al: CDKN2A loss is associated with shortened overall
survival in lower-grade (World Health Organization grades II–III)
astrocytomas. J Neuropathol Exp Neurol. 74:442–452. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Loriot Y, Schuler MH, Iyer G, Witt O, Doi
T, Qin S, Tabernero J, Reardon DA, Massard C, Palmer D, et al:
Tumor agnostic efficacy and safety of erdafitinib in patients (pts)
with advanced solid tumors with prespecified fibroblast growth
factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis
(IA) results. J Clin Oncol. 40 (16 Suppl):S30072022. View Article : Google Scholar
|
|
36
|
Costa R, Carneiro BA, Taxter T, Tavora FA,
Kalyan A, Pai SA, Chae YK and Giles FJ: FGFR3-TACC3 fusion in solid
tumors: Mini review. Oncotarget. 7:55924–55938. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang
Z, Dai Z, Zhang X, Zhang L, Peng Y, et al: Glioma targeted therapy:
Insight into future of molecular approaches. Mol Cancer. 21:392022.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Higa N, Akahane T, Hamada T, Yonezawa H,
Uchida H, Makino R, Watanabe S, Takajo T, Yokoyama S, Kirishima M,
et al: Detection of EGFR mutation distribution and transcriptional
variants in IDH-wildtype high-grade gliomas using a next-generation
sequencing oncopanel. Res Sq. 1–11. 2021.
|
|
39
|
Wang Y, Zhang J, Zhang P, Zhao Z, Huang Q,
Yun D, Chen J, Chen H, Wang C and Lu D: LZTR1 inactivation promotes
MAPK/ERK pathway activation in glioblastoma by stabilizing
oncoprotein RIT1. bioRxiv. 2020.
|
|
40
|
Frattini V, Trifonov V, Chan JM, Castano
A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, et al: The
integrated landscape of driver genomic alterations in glioblastoma.
Nat Genet. 45:1141–1149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Comba A, Faisal SM, Varela ML, Hollon T,
Al-Holou WN, Umemura Y, Nunez FJ, Motsch S, Castro MG and
Lowenstein PR: Uncovering spatiotemporal heterogeneity of
high-grade gliomas: From disease biology to therapeutic
implications. Front Oncol. 11:7037642021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sottoriva A, Spiteri I, Piccirillo SG,
Touloumis A, Collins VP, Marioni JC, Curtis C, Watts C and Tavaré
S: Intratumor heterogeneity in human glioblastoma reflects cancer
evolutionary dynamics. Proc Natl Acad Sci USA. 110:4009–4014. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tirrò E, Massimino M, Broggi G, Romano C,
Minasi S, Gianno F, Antonelli M, Motta G, Certo F, Altieri R, et
al: A custom DNA-based NGS panel for the molecular characterization
of patients with diffuse gliomas: Diagnostic and therapeutic
applications. Front Oncol. 12:8610782022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zou P, Xu H, Chen P, Yan Q, Zhao L, Zhao P
and Gu A: IDH1/IDH2 mutations define the prognosis and molecular
profiles of patients with gliomas: A meta-analysis. PLoS One.
8:e687822013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yan H, Parsons DW, Jin G, McLendon R,
Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ,
et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med.
360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sun H, Yin L, Li S, Han S, Song G, Liu N
and Yan C: Prognostic significance of IDH mutation in adult
low-grade gliomas: A meta-analysis. J Neurooncol. 113:277–284.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Park Y, Park J, Ahn JW, Sim JM, Kang SJ,
Kim S, Hwang SJ, Han SH, Sung KS and Lim J: Transcriptomic
landscape of lower grade glioma based on age-related non-silent
somatic mutations. Curr Oncol. 28:2281–2295. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ichimura K, Pearson DM, Kocialkowski S,
Bäcklund LM, Chan R, Jones DT and Collins VP: IDH1 mutations are
present in the majority of common adult gliomas but rare in primary
glioblastomas. Neuro Oncol. 11:341–347. 2009. View Article : Google Scholar : PubMed/NCBI
|
